报价延迟最少15分钟:2025/07/20 18:36 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.85 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.54/-1.94
|
|
企业价值
113.89M
|
| 资产负债 |
|
每股账面净值
0.50
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/20 18:36 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity. |
